Beijing, China, July 6, 2026 — Jacobio Pharma (1167.HK) today announced that its investee company GenEditBio Limited (“GenEditBio”) has received Investigational New Drug (IND) clearance from China’s National Medical Products Administration (NMPA) for GEB-101, its lead in vivo genome-editing program, to initiate a Phase 1/2 CLARITY clinical trial in China for TGFBI-related corneal dystrophies. GEB-101 previously received IND clearance from the U.S. Food and Drug Administration (FDA) in December 2025.

GEB-101 is a potential first-in-class in vivo genome-editing therapy developed by GenEditBio. It is designed as a single-administration treatment for corneal dystrophies caused by mutations in the TGFBI gene and is delivered via a single corneal intrastromal injection. The program is based on CRISPR-Cas genome-editing technology and leverages GenEditBio’s proprietary protein delivery vehicle (PDV) platform to deliver genome editors in the form of ribonucleoprotein complexes.

The NMPA clearance represents an important milestone in clinical development of GEB-101 in both China and the U.S., underscoring GenEditBio’s continued advancement in in vivo genome-editing delivery technologies and genetic ophthalmology. Jacobio made an early strategic investment in GenEditBio and has continued to follow the company’s development in genome editing and innovative delivery platforms. Looking forward, Jacobio will continue to evaluate emerging opportunities in novel therapeutic modality and support its portfolio companies in advancing innovative medicines that address significant unmet medical needs.

About Jacobio 
Jacobio Pharma (1167.HK) is committed to providing breakthrough treatments for patients. With an induced allosteric drug discovery platform, the company’s core projects focus on the KRAS pathway. The company envisions becoming a global leader in research and development, fostering strategic partnerships to drive innovation. Jacobio’s  R&D centers are located in Beijing, Shanghai (China), and Boston (USA). Clinical trials are conducted at over 180 sites in China, more than 30 sites in the USA, and over 10 sites across several European countries.

For more information, please visit: http: